The global Rituxan market, valued at USD 1,584.3 Mn in 2025, is expected to decline steadily to USD 1,082.1 Mn by 2032, exhibiting a negative compound annual growth rate (CAGR) of -5.3% from 2025 to 2032. While Rituxan, a monoclonal antibody targeting CD20 proteins on B-cells, has transformed the treatment of autoimmune disorders and hematological malignancies like rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, the market is facing challenges. The expiration of patents and increasing competition from biosimilars are expected to significantly affect the market share of Rituxan during the forecast period.
Market Dynamic
The decline in Rituxan's market is primarily attributed to the rising competition from biosimilars, which offer more affordable alternatives. Despite the drug's successful use in chronic conditions, the high cost of treatment remains a key constraint. Additionally, the potential side effects of Rituxan and the growing number of treatment options are likely to limit its use. However, opportunities exist in expanding Rituxan's indications for diseases such as multiple sclerosis and other autoimmune disorders, alongside new formulations and delivery methods like subcutaneous administration, which could improve patient convenience and mitigate some of the market's challenges.
Key Features of the Study
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on ‘Rituxan Market' - Global forecast to 2032
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
